The Journal of Practical Medicine >
Efficacy of ivabradine combined with levosimendan in patients with acute myocardial infarction complicated with heart failure
Received date: 2023-07-05
Online published: 2024-03-06
Objective To observe the efficacy of ivabradine combined with levosimendan in patients with acute myocardial infarction complicated with heart failure. Methods A total of 78 patients with acute myocardial infarction complicated with heart failure admitted to the hospital from May 1， 2020 to December 31， 2022 were selected and divided into control group （n = 39） and study group （n = 39） by random number table method. In addition to basic treatment，the control group received levosimendan， and the study group ivabradine and levosimendan. The treatment period of both groups was 4 weeks. Compare two groups of patients' vital signs， clinical curative effect and heart function index， serological indexes， inflammatory factors and security. Results Compared with before treatment， the systolic blood pressure， diastolic blood pressure and heart rate of the two groups were decreased after treatment （P < 0.05）， and the systolic blood pressure， heart rate， diastolic blood pressure and heart rate of the study group were significantly decreased compared with the control group （P < 0.05）. Compared with the control group， the total effective rate of the study group was significantly higher （P < 0.05）. Compared with before treatment， the levels of CO and LVEF were increased （P < 0.05）， while the levels of LVEDV and LVESV were decreased （P < 0.05）. Compared with the control group， the levels of CO and LVEF in the study group were higher （P < 0.05）， and the levels of LVEDV and LVESV in the study group were lower （P < 0.05）. Compared with before treatment， the levels of cTnI， sST2 and NT-proBNP in both groups were decreased after treatment （P < 0.05）， and the serum levels of cTnI， sST2 and NT-proBNP in the study group were significantly decreased compared with the control group （P < 0.05）. Tumor necrosis factor α （TNF-α）， myeloperoxidase （MPO） and highly sensitive C-reactive protein （hs-CRP） were all decreased after treatment in the two groups （P < 0.05）， and those in the study group were much lower （P < 0.05）No difference between the incidence of adverse reactions to the total contrast the two groups （P > 0.05）. Conclusion Levosimendan combined with ivabadinehave a definite effect on patients with acute myocardial infarction complicated with heart failure for the improved cardiac function， reduced inflammation， regulated serum sST2， cTnI， and NT-proBNP level. It is also safe and reliable
Xian WEN , Xianfeng ZENG , Ruiya SU . Efficacy of ivabradine combined with levosimendan in patients with acute myocardial infarction complicated with heart failure[J]. The Journal of Practical Medicine, 2024 , 40(2) : 242 -247 . DOI: 10.3969/j.issn.1006-5725.2024.02.020
| 1 | BARNETT C F， BRUSCA S B， HANFF T C， et al. Management of cardiogenic shock unrelated to acute myocardial infarction［J］. Can J Cardiol， 2023，39（4）：406-419. doi:10.1016/j.cjca.2023.01.023 |
| 2 | 帅梓强，张成鑫，安城，等. 中性粒细胞外陷阱与冠心病急性心肌梗死关联的临床流行病学研究［J］. 中华疾病控制杂志，2021，25（9）：1112-1116. |
| 3 | NAGELE M P， FLAMMER A J. Heart Failure After Right Ventricular Myocardial Infarction［J］. Curr Heart Fail Rep， 2022，19（6）：375-385. doi:10.1007/s11897-022-00577-8 |
| 4 | 黄奎，靳海斌，温小琴，等. 新型组织多普勒评价左西孟旦对射血分数降低的急性心力衰竭患者的短期持续影响［J］. 重庆医学，2021，50（1）：34-39. doi:10.3969/j.issn.1671-8348.2021.01.008 |
| 5 | SASMITA B R， XIE S， LIU G， et al. Ivabradine in patients with acute ST-elevation myocardial infarction： a meta-analysis of randomized controlled trials［J］. Egypt Heart J， 2023，75（1）：25. doi:10.1186/s43044-023-00351-8 |
| 6 | 李东义，李鹍，余东林. 伊伐布雷定片联合托伐普坦片治疗急性心肌梗死合并心力衰竭患者的临床研究［J］. 中国临床药理学杂志，2023，39（7）：928-931. |
| 7 | 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南（2019）［J］. 中华心血管病杂志，2019，47（10）：766-783. |
| 8 | 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018［J］. 中华心血管病杂志，2018，46（10）：760-789. doi:10.3760/cma.j.issn.0253-3758.2018.10.004 |
| 9 | JENCA D， MELENOVSKY V， STEHLIK J， et al. Heart failure after myocardial infarction： incidence and predictors［J］. ESC Heart Fail， 2021，8（1）：222-237. doi:10.1002/ehf2.13144 |
| 10 | 盛雪，纪征，王兆翔，等. 达格列净联合诺欣妥对急性心肌梗死患者急诊介入治疗后心力衰竭的疗效［J］. 实用医学杂志，2022，38（11）：1410-1414. doi:10.3969/j.issn.1006?5725.2022.11.020 |
| 11 | 王晓敏，徐亚威，毛云，等. 急性ST段抬高型心肌梗死伴射血分数减少型心力衰竭患者左心室逆重构的预测因素［J］. 实用医学杂志，2022，38（10）：1236-1239，1245. doi:10.3969/j.issn.1006-5725.2022.10.012 |
| 12 | HO M Y， WANG C Y. Role of irisin in myocardial infarction， heart failure， and cardiac hypertrophy［J］. Cells， 2021，10（8）：2013. doi:10.3390/cells10082103 |
| 13 | 叶恭杰，周建庆，袁园，等. 左西孟旦在改善ICU急性心肌梗死伴心力衰竭患者氧供-氧耗中的应用［J］. 中华急诊医学杂志，2021，30（9）：1070-1074. doi:10.3760/cma.j.issn.1671-0282.2021.09.005 |
| 14 | 伍鑫，王文艳，徐芸，等. 左西孟旦联合重组人脑利钠肽对急性失代偿性射血分数减低的心力衰竭患者的影响［J］. 中华老年心脑血管病杂志，2023，25（5）：465-468. doi:10.3969/j.issn.1009-0126.2023.05.005 |
| 15 | CHEN L， LI S， ZHU J， et al. Mangiferin prevents myocardial infarction-induced apoptosis and heart failure in mice by activating the Sirt1/FoxO3a pathway［J］. J Cell Mol Med， 2021，25（6）：2944-2955. doi:10.1111/jcmm.16329 |
| 16 | YE F， WANG X， WU S， et al. Sustained-release ivabradine hemisulfate in patients with systolic heart failure［J］. J Am Coll Cardiol， 2022，80（6）：584-594. doi:10.1016/j.jacc.2022.05.027 |
| 17 | ELSHERBINI H， SOLIMAN O， ZIJDERHAND C， et al. Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure： a systematic review and meta-analysis of 984 patients［J］. Heart Fail Rev， 2022，27（2）：493-505. doi:10.1007/s10741-021-10101-0 |
| 18 | 刘静，朱艳霞，邱翠婷，等. 伊伐布雷定对急性ST抬高型心肌梗死并左室射血分数降低型心力衰竭患者左心室重构指标的影响［J］. 中国医院药学杂志，2021，41（2）：183-190. |
| 19 | 杨威，吕媛媛，乾叶子，等. 芪苈强心胶囊口服辅助治疗前后心力衰竭患者血清NT-proBNP、BNP及sST2水平观察［J］. 山东医药，2021，61（30）：76-78. doi:10.3969/j.issn.1002-266X.2021.30.020 |
| 20 | CONCEICAO L， GOIS C， FERNANDES R， et al. Effect of ivabradine on exercise capacity in individuals with heart failure with preserved ejection fraction［J］. Heart Fail Rev， 2021，26（1）：157-163. doi:10.1007/s10741-020-10002-8 |
| 21 | CHAN C C， LEE K T， HO W J， et al. Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units： a multi-institution database study［J］. Ann Intensive Care， 2021，11（1）：27. doi:10.1186/s13613-021-00810-y |
| 22 | 赵伟新，王朋飞，夏贵山，等. 右美托咪定对PCI老年急性心肌梗死患者氧化应激和炎症反应的影响［J］. 中国老年学杂志，2022，42（12）：2921-2924. doi:10.3969/j.issn.1005-9202.2022.12.021 |
| 23 | 武智晓，李杰，王勃. 外周血MPO、NLR、hs-CRP对ST段抬高型心肌梗死患者PCI术后主要不良心脏事件的预测价值［J］. 中国现代医学杂志，2022，32（6）：90-96. doi:10.3969/j.issn.1005-8982.2022.06.016 |
| 24 | 叶为，刘小燕，赵茂宇，等. 慢性心力衰竭患者血清hs-CRP、sST2水平与心脏再同步化治疗后室性心律失常的相关性［J］. 疑难病杂志，2023，22（6）：566-571，577. doi:10.3969/j.issn.1671-6450.2023.06.002 |
| 25 | 梁妍，陈俊先，张芝帅，等. 伊伐布雷定联合比索洛尔在老年慢性射血分数降低心力衰竭合并慢性阻塞性肺疾病中的应用价值［J］. 中国老年学杂志，2023，43（4）：781-784. doi:10.3969/j.issn.1005-9202.2023.04.004 |
/
| 〈 |
|
〉 |